Aldeyra Therapeutics Inc (STU:137)

€ 5.196 0.038 (0.74%) Market Cap: 265.33 Mil Enterprise Value: 167.12 Mil PE Ratio: 0 PB Ratio: 2.88 GF Score: 38/100

Aldeyra Therapeutics Inc ADX-629 Results Call Transcript
Dec 19, 2023
Aldeyra Therapeutics Inc Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 Call Transcript
Jun 29, 2023
Aldeyra Therapeutics Inc Top-Line Results from the Phase 2 Clinical Trial of ADX-629 in Patients with Chronic Cough Call Transcript
Jun 27, 2023
Aldeyra Therapeutics Inc Top-Line Results from the Phase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis Call Transcript
Jun 15, 2023
Aldeyra Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q4 2022 Aldeyra Therapeutics Inc Earnings Call Transcript
Mar 09, 2023

€6.91 (-0.49%)

Earnings
Q3 2022 Aldeyra Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

€5.1 (-2.37%)

Earnings
Aldeyra Therapeutics Inc to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Call Transcript
Oct 06, 2022
Q2 2022 Aldeyra Therapeutics Inc Earnings Call Transcript
Aug 05, 2022

€6.86 (+18.92%)

Earnings
Aldeyra Therapeutics Inc Call to Report Top-Line Results from the Crossover Clinical Trial of Reproxalap Transcript
Jul 12, 2022
Aldeyra Therapeutics Inc TRANQUILITY-2 Top-Line Data Results Call Transcript
Jun 08, 2022
Q1 2022 Aldeyra Therapeutics Inc Earnings Call Transcript
May 05, 2022

€2.65 (-1.38%)

Earnings
Aldeyra Therapeutics Inc Research & Development Day Transcript
Mar 29, 2022
Q4 2021 Aldeyra Therapeutics Inc Earnings Call Transcript
Mar 17, 2022

€3.68 (+1.10%)

Earnings
Aldeyra Therapeutics Inc Conference Call and Webcast Transcript
Dec 20, 2021
Q3 2021 Aldeyra Therapeutics Inc Earnings Call Transcript
Oct 28, 2021

€7.6 (+7.04%)

Earnings
Aldeyra Therapeutics Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2021
Q2 2021 Aldeyra Therapeutics Inc Earnings Call Transcript
Aug 05, 2021

€8 (+6.67%)

Earnings
Q1 2021 Aldeyra Therapeutics Inc Earnings Call Transcript
May 06, 2021

€9.6 (-2.54%)

Earnings
Aldeyra Therapeutics Inc Provide Results from the Phase 3 Invigorate Clinical Trial Corporate Call Transcript
Apr 27, 2021
Q4 2020 Aldeyra Therapeutics Inc Earnings Call Transcript
Mar 11, 2021

€9.9 (+2.59%)

Earnings
Aldeyra Therapeutics, Inc. - Special Call Transcript
Jan 07, 2021
Q3 2020 Aldeyra Therapeutics Inc Earnings Call Transcript
Nov 05, 2020

€5.9 (+2.61%)

Earnings
Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel Transcript
Sep 10, 2020
Q2 2020 Aldeyra Therapeutics Inc Earnings Call Transcript
Aug 06, 2020

€5.6 (-8.20%)

Earnings
Aldeyra Therapeutics, Inc. - Special Call Transcript
May 20, 2020
Q1 2020 Aldeyra Therapeutics Inc Earnings Call Transcript
May 07, 2020

€2.7 (-0.74%)

Earnings
Q4 2019 Aldeyra Therapeutics Inc Earnings Call Transcript
Mar 12, 2020

€2.34 (-8.59%)

Earnings
Aldeyra Therapeutics Inc Corporate Analyst Meeting Transcript
Feb 24, 2020
Aldeyra Therapeutics, Inc. - Special Call Transcript
Dec 03, 2019
Q3 2019 Aldeyra Therapeutics Inc Earnings Call Transcript
Nov 07, 2019

€5.05 (-7.34%)

Earnings
Aldeyra Therapeutics, Inc. - Special Call Transcript
Oct 31, 2019
Q2 2019 Aldeyra Therapeutics Inc Earnings Call Transcript
Aug 08, 2019

€4.68 (-2.24%)

Earnings
Aldeyra Therapeutics, Inc. - Special Call Transcript
Jun 25, 2019
Q1 2019 Aldeyra Therapeutics Inc Earnings Call Transcript
May 09, 2019

€7.08 (-0.23%)

Earnings
Aldeyra Therapeutics, Inc. - Special Call Transcript
Mar 26, 2019
Q4 2018 Aldeyra Therapeutics Inc Earnings Call Transcript
Mar 08, 2019

€6.61 (-4.20%)

Earnings
Aldeyra Therapeutics, Inc. - Special Call Transcript
Feb 28, 2019

Aldeyra Therapeutics, Inc. - Special Call Transcript

Jun 25, 2019 / 12:00PM GMT

Release Date Price: €4.43 (-28.35%)

Transcript

Operator

Good morning. My name is Jessa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Aldeyra Therapeutics announces top line results from the SOLACE trial.

(Operator Instructions) Thank you.

Mr. Joshua Reed, Chief Financial Officer, you may begin your conference.

Joshua Reed

Aldeyra Therapeutics, Inc. - CFO

Good morning, everyone. I'm Joshua Reed, Chief Financial Officer of Aldeyra Therapeutics, and welcome to the Aldeyra Therapeutics conference call to discuss the results from the SOLACE trial in noninfectious anterior uveitis.

With me today is Dr. Todd Brady, President and Chief Executive Officer; and Dr. David Clark, Chief Medical Officer.

This conference call contains forward-looking statements regarding future events and the future performance of Aldeyra. Forward-looking statements include statements regarding Aldeyra's possible or assumed future results of operations; expenses and financial position; business strategies and plans; research, development and commercial

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.